B7H3-targeted CAR-Ts have demonstrated significant cytotoxic effects in animal models, and B7H3 inhibitors have reversed the abnormal tumor metabolism [12], suggesting that reducing B7H3 is beneficial for improving clinical outcomes. This evidence concerns the gene CD276 and neoplasm.